User:Mr. Ibrahem/Amivantamab

Amivantamab, sold under the brand name Rybrevant, is a medications used to treat non-small cell lung cancer. Specifically it is used for advanced cases with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, who have failed other treatments. It is given by injection into a vein.

Common side effects include rash, infusion reaction, infection around the nail, muscle and joint pain, shortness of breath, nausea, tiredness, swelling, sores in the mouth, cough, and constipation. Other side effects may include pneumonitis, eye problems, low potassium, high blood sugar, low sodium, and liver inflammation. Use in pregnancy may harm the baby. It is a bispecific monoclonal antibody that attaches to epidermal growth factor (EGF) receptor and mesenchymal–epithelial transition (MET) receptor.

Amivantamab was approved for medical use in the United States and Europe in 2021. In the United Kingdom it costs the NHS about £1,100 for a 350 mg vial as of 2022. This amount in the United States costs about 3,500 USD.